Health Canada has issued a strong warning against the purchase and use of unauthorized or counterfeit GLP-1 drugs, including the widely recognized semaglutide, an active ingredient...
Novo Nordisk has secured approval from the U.S. Food and Drug Administration (FDA) to market its oral GLP-1 medication, Rybelsus, specifically aimed at reducing the risk...